Gotoh M, Takiuchi H, Hirata I, Iyama M, Inoue R, Itabashi T, Egashira Y, Inoue T, Kurisu Y, Tanaka M, Shimamoto C, Katsu K
Division of Internal Medicine, Hokusetsu General Hospital.
Gan To Kagaku Ryoho. 1999 May;26(6):837-9.
A 79-year-old male was admitted to our hospital for further examination on gastric carcinoma (1' type) in the cardia. The histology of biopsied tissue was moderately differentiated adenocarcinoma (tub2). The patient refused a gastrectomy and received three cycles of local injection therapy with OK-432 + Beriplast into the tumor. However, the tumor showed no decrease in size. Considering the quality of life, the patient was given out patient treatment with 5'-DFUR (Furtulon, 800 mg/day). Three months later, the patient showed a partial response (PR) on the basis of gastric X-ray and endoscopic findings. No adverse reactions to the drug were seen. The patient has been receiving the same drug since then, and has continued to show PR for 15 months. Biopsied tissues were checked immunohistochemically for expression of thymidine phosphorylase (TdRPase), and changes in tissue TdRPase level were examined by ELISA. The TdRPase level decreased with shrinking of the tumor. These results suggest that the shrinking of tumor following 5'-DFUR therapy is closely related to TdRPase.
一名79岁男性因贲门部胃癌(1型)入院接受进一步检查。活检组织的组织学检查为中分化腺癌(tub2)。患者拒绝接受胃切除术,接受了三个周期的肿瘤局部注射OK-432加贝瑞普利治疗。然而,肿瘤大小未减小。考虑到生活质量,给予患者口服5'-DFUR(喃氟啶,800毫克/天)门诊治疗。三个月后,根据胃部X线和内镜检查结果,患者显示部分缓解(PR)。未观察到该药物的不良反应。此后患者一直服用相同药物,持续显示PR达15个月。对活检组织进行免疫组织化学检查以检测胸苷磷酸化酶(TdRPase)的表达,并通过酶联免疫吸附测定法检测组织TdRPase水平的变化。TdRPase水平随肿瘤缩小而降低。这些结果表明,5'-DFUR治疗后肿瘤缩小与TdRPase密切相关。